Iovance Biotherapeutics is now up 78% in a single month and the short book, despite a week of further trimming, remains one of the heaviest in biotech — a standoff that grows more expensive for bears with each passing session.
Short interest has edged down again, falling about 0.9% on the week to 23.2% of the free float — roughly 92 million shares. That continues the slow bleed that began in mid-July, when short interest topped 121 million shares. But context matters: the pace of covering is glacial relative to the scale of the rally. A month ago, over 123 million shares were short. Since then the stock has nearly doubled, and bears have returned only about 30 million shares. The borrow market has loosened considerably alongside it — availability expanded sharply this week, rising 82% to 137.6%, meaning the lending pool now holds well over one share available for every share already borrowed. Cost to borrow remains low at 0.59%, barely changed from recent weeks. Together, those conditions describe a short book that is uncomfortable but not mechanically forced — there is no squeeze dynamic in the lending market, even as the stock grinds higher.
Options positioning has tightened further toward defensiveness. The put/call ratio reached 0.358 on Friday — above the 52-week high of 0.3665 on an intraday basis and running nearly two standard deviations above its 20-day average of 0.308. That is the most protective options stance of the past year. The direction of travel in PCR and SI is now diverging: short sellers are covering at the margin while options traders are adding downside protection. Both groups are cautious, but they are cautious in different ways — the shorts are slowly giving ground, the options market is hedging against a reversal.
Analyst reaction to the Q2 print has been constructive. Barclays raised its target to $13 from $11 while maintaining Overweight, and Citizens lifted to $8 from $5. The mean target across the coverage universe is $9.22, which implies about 32% upside from the current $6.98 close. The bull case centres on Iovance's T-cell therapy pipeline and Amtagvi commercial momentum; bears flag FDA scrutiny and the complexity of scaling personalised TIL manufacturing. The ORTEX short score is still elevated at 71.7 — high on an absolute basis but down from 74.7 on August 6, the day of the earnings spike, suggesting the composite signal has eased modestly as the borrow loosened and short interest dipped.
On the institutional side, BlackRock added 5.9 million shares in the most recent filing period through July 31, lifting its stake to 8.2% of shares outstanding. State Street added 7 million shares in the same window, moving to 5.4%. That is two of the three largest passive holders actively adding — a notable flow given that the stock was trading near multi-month lows for much of July. Among peers, PTGX gained 6.3% on the week and VIR added 4.8%, while IPSC fell 4% — the biotech space is not moving uniformly, which makes IOVA's continued outperformance more stock-specific than sector-driven.
The August 6 earnings print produced a 46% single-day move and a 50% five-day move. The next earnings event is scheduled for November 6. Between now and then, the key watch is whether the short book — still 23% of float and not under mechanical pressure — begins to cover more aggressively, or whether the easy borrow conditions attract fresh positioning as the stock consolidates.
See the live data behind this article on ORTEX.
Open IOVA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
